The globally acting company Aimedis is thriving because of the growing number of key players joining Aimedis Avalon, the first metaverse platform developed for the healthcare industry. Starting Monday, 29 August 2022, the Aimedis token AIMX will be traded on BitMart, one of the most trusted cryptocurrency trading platforms.
Aimedis-founder and CEO Michael J. Kaldasch explains: “We are glad to announce that the Aimedis token AIMX will be traded in BitMart.” The user-friendly cryptocurrency trading platform BitMart with more than 2,2 million international users believes in decentralized digital currency available for everyone, everywhere and offers real-time trading services, including well established cryptocurrencies like Bitcoin and Ethereum. Kaldasch adds: “This is the next logical step for our company as we are continuously growing by teaming up with new partners and important clients.”
Well-known university hospitals are among the latest Aimedis Avalon clients as well as the international healthcare agency network HAVAS Healthcare & You/HAVAS NOW and major pharma companies. Ben El Idrissi, COO and also founder of Aimedis, explains: “Aimedis Avalon is a secure metaverse platform, offering services, support and advice to patients, doctors and healthcare professionals and it additionally makes educational information available for patients and students all over the world.” He concludes: “We just participated in the APAC Patient Experience Innovation Summit in Bangkok with Stefan Wiesner, our CTO, as panel speaker and met a lot of interest of South East Asia based healthcare companies and hospital chains, of whom a lot are going to go into the metaverse via Aimedis Avalon.”
Aimedis is also planning to start the second landsale within the next weeks to press ahead the revolutionizing of the healthcare industry.
Media Contact:
Name- Hanna Pollmann, Press Relations Officer Aimedis
Email- hanna.pollmann@aimedis.com,
Phone Number- +491784772640
Website- https://aimedis.io/
Telegram- AimedisOfficialEnglish
Discord- Aimedis
Twitter- Aimedis
